Founded in 2002, PolyMedix is a publically held biotechnology company that develops drugs and biomaterials for the treatment of life-threatening disorders. The company produces medications for infectious diseases and cardiovascular disorders. It provides antibiotic compounds for the treatment of systemic and local infections. The company also develops several polymeric formulations, such as antimicrobial biomaterials that are used as additives for paints, plastics and textiles. It provides a variety of anticoagulant antagonist compounds that reverse the activity of low-molecular weight heparins. In addition, some of the drugs provided by the company feature membrane and protein and protein and protein interactions. PolyMedix offers various drug programs, as well as conducts clinical trials.
Partial Data by Infogroup (c) 2024. All rights reserved.